WuXi PharmaTech Completes Construction of New Biosafety Testing Facility
News May 13, 2014
The facility consists of 38,000 square feet of laboratories and support areas in a building adjacent to WuXi's GLP preclinical drug safety facility. Operations will begin after validations are completed this summer. Service offerings will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for Chinese and multinational customers.
The new services will expand WuXi's already broad, integrated platform of biologics services. In the United States, WuXi offers biosafety testing services such as viral clearance validation and lot release and stability testing. In China, the company's services include novel monoclonal antibody discovery, discovery biology, drug screening, cell-line engineering and construction, toxicology, bioanalytical services, assay development, formulation, process development, and cGMP drug-substance and drug-product manufacturing for clinical trials.
"WuXi's expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "By investing in capabilities that address our customers' needs, we have become a leading biologics solution provider."
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019